Purpose Over the past 20 years results of clinical trials have provided information that has
revolutionized the approach to management of venous thromboembolic disease. New …

Bleeding after CPB has been difficult to characterize and its treatment equally difficult to
standardize. The complexity of this problem is related to the hemostatic process, the …

Background Heparin-induced thrombocytopenia, defined by the presence of heparin-
dependent IgG antibodies, typically occurs five or more days after the start of heparin …

Background Heparin-induced thrombocytopenia is a relatively common antibody-mediated
drug reaction. We studied the temporal relation between previous or current heparin therapy …

Heparin-induced thrombocytopenia can be a serious and difficult-to-diagnose complication
of heparin therapy. Serum from patients with heparin-induced thrombocytopenia can cause …

Background—Heparin-induced thrombocytopenia (HIT) is an immune-mediated syndrome
caused by heparin. Complications range from thrombocytopenia to thrombocytopenia with …

This report describes studies into the pathophysiology of heparin-induced
thrombocytopenia. The IgG fraction from each of nine patients with heparin-induced …

Heparin is the anticoagulant of choice when a rapid anticoagulant effect is required because
its onset of action is immediate when administered by IV injection. Heparin is administered …

(CHEST 1998; 114: 489$—5IOS) H eparin and its derivative, low-molecular—weight hep-
arin (LMWII), are the anticoagulants of choice when a rapid anticoagulant effect is required …

In 1991, about 500000 Americans had a stroke (400 000 had an ischemic stroke) and more
than 143 000 died.'More than 3 000 000 people in the United States have survived a stroke …